Physician profile
Stephen E Sacks
NPI 1528156635
$5,380.91
in general payments reported to CMS, 2019-2025
33 companies · $1,379 in 2025
The $1,379 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $603 · 2020: $582 · 2021: $707 · 2022: $500 · 2023: $732 · 2024: $878 · 2025: $1,379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,989.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,989.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $747.55 | 2022-2025 | Mavenclad, Mavenclad |
| Biogen, INC. | $652.31 | 2019-2025 | Tysabri, Vumerity |
| Argenx US, INC. | $590.91 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Neurocrine Biosciences, INC. | $581.76 | 2019-2025 | Ingrezza, Ongentys |
| Novartis Pharmaceuticals Corporation | $569.51 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $388.08 | 2019-2025 | Austedo, Austedo Xr |
| Acorda Therapeutics, INC | $301.63 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $166.40 | 2021-2025 | Wainua |
| Abbvie INC. | $165.15 | 2021-2025 | Qulipta |
| Tg Therapeutics, INC. | $155.14 | 2025 | |
| Ani Pharmaceuticals, INC. | $114.78 | 2024-2025 | Purified Cortrophin Gel |
| Ucb, INC. | $112.13 | 2019-2022 | |
| Amgen INC. | $111.61 | 2020 | |
| Genzyme Corporation | $70.36 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $62.72 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $61.00 | 2019-2021 | |
| Celgene Corporation | $54.57 | 2021-2022 | |
| Adamas Pharmaceuticals, INC. | $51.73 | 2019 | |
| Mdd US Operations, LLC | $45.67 | 2022-2025 | |
| Supernus Pharmaceuticals, INC. | $42.80 | 2019-2021 | |
| Neurelis, INC. | $42.40 | 2024-2025 | Valtoco |
| Sk Life Science, INC. | $37.99 | 2023 | |
| Kyowa Kirin, INC. | $32.56 | 2021 | |
| Astellas Pharma US INC | $30.49 | 2025 | Xtandi |
| Blue Earth Diagnostics | $30.28 | 2025 | Posluma |
| Sumitomo Pharma America, INC. | $29.93 | 2023 | Aptiom |
| Acadia Pharmaceuticals INC | $28.66 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $21.32 | 2021 | |
| Vertical Pharmaceuticals, LLC | $21.21 | 2019 | |
| Eisai INC. | $19.27 | 2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $16.24 | 2022 | |
| Tanabe Pharma America, INC. | $12.62 | 2021 | |
| Merck Sharp & Dohme LLC | $12.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Sacks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.